Novus Therapeutics Announces Acquisition Of Anelixis Therapeutics

Novus Therapeutics, Inc. Announced It Has Completed The Acquisition Of Anelixis Therapeutics, Inc. (&Ldquo;Anelixis&Rdquo;), A Privately Held Clinical Stage Biotechnology Company Developing A Next Generation Anti-Cd40 Ligand (Cd40L) Antibody As A Potential Treatment For Organ And Cellular Transplantation, Autoimmune Diseases, And Neurodegenerative Diseases. Concurrent With The Acquisition Of Anelixis, Novus Entered Into A Definitive Agreement For The Sale Of Non-Voting Convertible Preferred Stock (The &Ldquo;Preferred Stock&Rdquo;) In A Private Placement To A Group Of Institutional Accredited Investors Led By Bvf Partners L.P., With Participation From Cormorant Asset Management, Ecor1 Capital, Logos Capital, Fidelity Management And Research Company, Adage Capital Partners L.P., Woodline Partners Lp, Ridgeback Capital, Janus Henderson Investors, And Samsara Biocapital, As Well As Additional Investors. The Private Placement Is Expected To Result In Gross Proceeds To Novus Of Approximately $108 Million Before Deducting Placement Agent And Other Offering Expenses. The Proceeds From The Private Placement Will Be Used To Fund The Company&Rsquo;S Operations, Including To Advance Phase 2 Clinical Trials Of At-1501, A Humanized Igg1 Anti-Cd40L Antibody With High Affinity For Cd40L, In Renal Transplantation, Islet Cell Transplantation, Autoimmune Nephritis, And Amyotrophic Lateral Sclerosis (Als).&Ldquo;We Are Excited About At-1501 And The Potential To Develop And Commercialize The Next Generation Anti-Cd40L Antibody, A Well-Validated Target With Broad Therapeutic Possibilities,&Rdquo; Said Keith A. Katkin, Chairman Of The Board Of Directors Of Novus. &Ldquo;After Exploring A Range Of Strategic Options To Maximize Shareholder Value, We Believe This Acquisition Represents The Greatest Value Creation Opportunity For Novus Stockholders, And We Are Confident That We Have The Management And Scientific Leadership Team To Fully Realize This Opportunity For Patients In Need Of New Treatment Options

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!